Multiple Sclerosis

Multiple sclerosis is a chronic immune-mediated disease of the central nervous system in which inflammation, demyelination, and axonal loss produce lesions disseminated in space and time. It typically begins in young adulthood with relapsing neurological episodes and, in many people, evolves over time toward progressive disability driven by neurodegeneration.

Definition

Multiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system characterised by immune-mediated lesions (plaques) of myelin loss with relative axonal damage, disseminated in space and time, producing varied and often relapsing neurological deficits.

Scope

This topic covers multiple sclerosis as a clinical and biological entity: its inflammatory demyelinating pathology together with its neurodegenerative component, the relapsing and progressive disease courses, the principle of dissemination in space and time underlying diagnosis, and its epidemiology. It is a reference overview and does not provide diagnostic protocols or treatment guidance.

Core questions

• How do inflammation and demyelination relate to long-term neurodegeneration?
• What underlies the shift from relapsing to progressive disease?
• How is dissemination in space and time established for diagnosis?
• Why does susceptibility vary with geography, genetics, and environment?

Key concepts

• Inflammatory demyelinating plaques
• Dissemination in space and time
• Relapsing-remitting and progressive courses
• Axonal loss and neurodegeneration
• MRI lesions and oligoclonal bands
• Geographic and genetic susceptibility
• McDonald diagnostic criteria

Key theories

Immune-mediated demyelination with neurodegeneration

Multiple sclerosis is understood as an immune-mediated attack on central nervous system myelin that produces focal inflammatory plaques, alongside a neurodegenerative process of axonal and neuronal loss that accumulates over time and drives progressive disability.

Dissemination in space and time

Diagnosis rests on demonstrating lesions disseminated in space (multiple central nervous system locations) and in time (occurring at different times), a principle operationalised and refined by the McDonald criteria using clinical and MRI evidence.

Mechanisms

In multiple sclerosis, immune cells cross the blood-brain barrier and mount an attack on central nervous system myelin, producing focal inflammatory demyelinating plaques in the brain, optic nerves, and spinal cord. Demyelination slows or blocks nerve conduction and, together with axonal and neuronal injury, generates the relapsing deficits and the accumulating, often progressive disability. The pathology is disseminated in space and time, and the interplay between focal inflammation and a more diffuse neurodegenerative process is thought to underlie the transition from a relapsing-remitting to a progressive course (Reich et al., 2018; Thompson et al., 2018).

Clinical relevance

Multiple sclerosis is a leading cause of non-traumatic neurological disability in young adults, and understanding its combined inflammatory and neurodegenerative pathology underpins how its relapsing and progressive courses are recognised and how diagnosis is framed around dissemination in space and time. This entry describes how the disease is defined and studied; it is not a basis for individual diagnosis or treatment decisions.

Epidemiology

Multiple sclerosis most often begins between about 20 and 40 years of age and is more common in women than men. Its prevalence varies markedly with geography, generally increasing with latitude, and reflects a combination of genetic susceptibility and environmental factors such as vitamin D status, Epstein-Barr virus exposure, and smoking (Reich et al., 2018).

History

Jean-Martin Charcot gave the first detailed clinical and pathological account of multiple sclerosis in the 1860s, linking its varied neurological signs to disseminated sclerotic plaques. The twentieth and twenty-first centuries clarified its immune-mediated demyelinating nature, recognised the importance of axonal loss and neurodegeneration to progressive disability, and introduced MRI-based diagnostic frameworks such as the McDonald criteria that operationalise dissemination in space and time (Reich et al., 2018; Thompson et al., 2018).

Debates

How should the inflammatory and neurodegenerative components be weighted?

There is ongoing discussion about the relative contributions of focal inflammation and diffuse neurodegeneration to progressive disability, with implications for how progressive disease is understood and classified.

Key figures

• Jean-Martin Charcot
• Daniel Reich
• Claudia Lucchinetti
• Alan Thompson

Seminal works

• reich-2018
• thompson-2018
• dugger-dickson-2017

Frequently asked questions

What does dissemination in space and time mean?

It is the core diagnostic principle of multiple sclerosis: evidence that the disease has affected more than one location in the central nervous system (space) and has been active at more than one time point (time), shown through clinical episodes and MRI findings.

Is multiple sclerosis an inflammatory or a degenerative disease?

It is both: an immune-mediated inflammatory disease that damages myelin, accompanied by a neurodegenerative process of axonal and neuronal loss that contributes to progressive disability over time.